Karoly Toth

Dr. Karoly Toth

orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2014 in Current Gene Therapy
Verified
Journal Article
Closed access
PDF file
WWWilliam Wold
William Wold
KTKaroly Toth
Karoly Toth
Adenovirus vectors are the most commonly employed vector for cancer gene therapy. They are also used for gene therapy and as vaccines to express foreign antigens. Adenovirus vectors can be replication-defective; certain essential viral genes are deleted and replaced by a cassette that expresses a foreign therapeutic gene. Such vectors are used for gene therapy, as vaccines, and for cancer therapy. Replication-competent (oncolytic) vectors are employed for cancer gene therapy. Oncolytic vectors are engineered to replicate preferentially in cancer cells and to destroy cancer cells through the natural process of lytic virus replication. Many clinical trials indicate that replication-defective and replication-competent adenovirus vectors are safe and have therapeutic activity.

1 May 2012 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
PRPeng Ru
Peng Ru
RSRobert Steele
Robert Steele
PNPhilip Newhall
Philip Newhall
NPNancy J. Phillips
Nancy J. Phillips
KTKaroly Toth
Karoly Toth
RRRatna B. Ray
Ratna B. Ray
Prostate cancer remains the second leading cause of cancer deaths among American men. Early diagnosis increases survival rate in patients; however, treatments for advanced disease are limited to hormone ablation techniques and palliative care. Thus, new methods of treatment are necessary for inhibiting prostate cancer disease progression. Here, we have shown that miRNA-29b (miR-29b) expression was lower in prostate cancer cells (PC3 and LNCaP) as compared with immortalized prostate epithelial cells. Between these two prostate cancer cell lines, metastatic prostate cancer PC3 cells displayed lower expression of miR-29b. We also observed a significant downregulation of miR-29b expression in human prostate cancer tissues as compared with patient-matched nontumor tissues. PC3 cells ectopically expressing miR-29b inhibited wound healing, invasiveness, and failed to colonize in the lungs and liver of severe combined immunodeficient mice after intravenous injection, while PC3 cells expressing a control miRNA displayed metastasis. Epithelial cell marker E-cadherin expression was enhanced miR-29b transfected in prostate cancer cells as compared with cells expressing control miRNA. On the other hand, N-cadherin, Twist, and Snail expression was downregulated in PC3 cells expressing miR-29b. Together these results suggested that miR-29b acts as an antimetastatic miRNA for prostate cancer cells at multiple steps in a metastatic cascade. Therefore, miR-29b could be a potentially new attractive target for therapeutic intervention in prostate cancer. Mol Cancer Ther; 11(5); 1166–73. ©2012 AACR.

1 April 1998 in Nature
Verified
Journal Article
Closed access
PDF file
ATAnn E. Tollefson
Ann E. Tollefson
THTerry W. Hermiston
Terry W. Hermiston
DLDrew L. Lichtenstein
Drew L. Lichtenstein
CCClarence F. Colle
Clarence F. Colle
Ralph TrippRalph Tripp
Ralph Tripp
WWWilliam S. M. Wold
William S. M. Wold

1 July 2000 in Journal of Virology
Verified
Journal Article
Closed access
PDF file
KDKonstantin Doronin
Konstantin Doronin
KTKaroly Toth
Karoly Toth
MKMohan Kuppuswamy
Mohan Kuppuswamy
PWPeter Ward
Peter Ward
ATAnn E. Tollefson
Ann E. Tollefson
WWWilliam Wold
William Wold
We have constructed two novel adenovirus (Ad) replication-competent vectors, named KD1 and KD3, that may have use in anticancer therapy. The vectors have two key features. First, they markedly overexpress the Ad death protein (ADP), an Ad nuclear membrane glycoprotein required at late stages of infection for efficient cell lysis and release of Ad from cells. Overexpression of ADP was achieved by deleting the E3 region and reinserting theadpgene. Because ADP is overexpressed, KD1 and KD3 are expected to spread more rapidly and effectively through tumors. Second, KD1 and KD3 have two E1A mutations (from the mutantdl1101/1107) that prevent efficient replication in nondividing cells but allow replication in dividing cancer cells. These E1A mutations preclude binding of E1A proteins to p300 and pRB. As a result, the virus should not be able to drive cells from G0to S phase and therefore should not be able to replicate in normal tissues. We show that KD1 and KD3 do not replicate well in quiescent HEL-299 cells or in primary human bronchial epithelial cells, small airway epithelial cells, or endothelial cells; however, they replicate well in proliferating HEL-299 cells and human A549 lung carcinoma cells. In cultured A549 cells, KD1 and KD3 lyse cells and spread from cell to cell more rapidly than their control virus,dl1101/1107, or wild-type Ad. They are also more efficient thandl1101/1107 or wild-type Ad in complementing the spread from cell to cell of an E1−E3−replication-defective vector expressing β-galactosidase. A549 cells form rapidly growing solid tumors when injected into the hind flanks of immunodeficient nude mice; however, when A549 cells were infected with 10−4PFU of KD3/cell prior to injection into mice, tumor formation was nearly completely suppressed. When established A549 tumors in nude mice were examined, tumors injected with buffer grew 13.3-fold over 5 weeks, tumors injected withdl1101/1107 grew 8-fold, and tumors injected with KD1 or KD3 grew 2.6-fold. Hep 3B tumors injected with buffer grew 12-fold over 3.5 weeks, whereas tumors injected with KD1 or KD3 grew 4-fold. We conclude that KD1 and KD3 show promise as anticancer therapeutics.

1 August 1999 in Current Opinion in Immunology
Verified
Journal Article
Closed access
WWWilliam Wold
William Wold
KDKonstantin Doronin
Konstantin Doronin
KTKaroly Toth
Karoly Toth
MKMohan Kuppuswamy
Mohan Kuppuswamy
DLDrew L Lichtenstein
Drew L Lichtenstein
ATAnn E Tollefson
Ann E Tollefson

1 February 2006 in Cancer Research
Verified
Journal Article
Open access
PDF file
MTMaria A. Thomas
Maria A. Thomas
JSJacqueline F. Spencer
Jacqueline F. Spencer
MRMarie C. La Regina
Marie C. La Regina
DDDebanjan Dhar
Debanjan Dhar
ATAnn E. Tollefson
Ann E. Tollefson
WWWilliam S.M. Wold
William S.M. Wold
Oncolytic adenoviruses represent an innovative approach to cancer therapy. These vectors are typically evaluated in immunodeficient mice with human xenograft tumors. However, in addition to being immunodeficient, this model is limited because normal and cancerous mouse tissues are poorly permissive for human adenovirus replication. This prompted us to search for a model that more accurately reflects the use of oncolytic adenoviruses in cancer patients. To this end, we developed a novel Syrian hamster model that is both immunocompetent and replication-permissive. We found that human adenovirus replicates well in Syrian hamster cell lines and confirmed replication in the lungs. Oncolytic adenovirus injection showed efficacy in three different hamster tumor models. Furthermore, i.t. oncolytic adenovirus injection resulted in suppression of primary and metastatic lesions, i.t. replication and necrosis, vector entrance into the bloodstream, replication in the liver and lungs, and anti-adenovirus antibody induction. Our findings show that the Syrian hamster is a promising immunocompetent model that is permissive to human adenovirus replication in tumors as well as normal tissues. Therefore, the Syrian hamster model may become a valuable tool for the field of oncolytic adenovirus vectors in which vector safety and efficacy can be evaluated. (Cancer Res 2006; 66(3): 1270-6)